Drugs / Recombinant Human Erythropoietin Alpha
Recombinant Human Erythropoietin Alpha
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT00399269 | Dec 2006 → Jun 2007 | anemia | Cadila Pharnmaceuticals | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT05373303 Comparator | Nov 2019 → May 2021 | chronic kidney disease | PT. Daewoong Infion | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Human Erythropoietin Alpha | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05373303 ↗ |
| Known as | Epoetin alfa | “Epoetin alfa, a 165 amino acid glycoprotein manufactured by recombinant DNA technology, has the same biological effects as endogenous rHu-EPO.” NCT00399269 ↗ |
| Known as | Recombinant Human Erythropoietin Alfa | “Recombinant Human Erythropoietin Alfa, dosage : 50 IU/Kg body weight three times per week, and continued to titrated dose closely to achieve baseline Hb level 10-12g/dL” NCT05373303 ↗ |
| Known as | rhEPO | “recombinant human erythropoietin (rhEPO) manufactured by Daewoong Pharmaceutical Co., Ltd” NCT05373303 ↗ |
| Known as | rHu-EPO-alpha | “To establish the efficacy and Safety of rHu-EPO-alpha in patients with anemia of Chronic Renal Failure.” NCT00399269 ↗ |
| Modality | Protein / enzyme biologic | “Epoetin alfa, a 165 amino acid glycoprotein manufactured by recombinant DNA technology” NCT00399269 ↗ |
| Route | Intravenous | “through intravenous injection” NCT05373303 ↗ |